Panellists in this video:
• Prof Vandana B. Patravale, Professor of Pharmaceutics, Institute of Chemical Technology(Moderator)
• Dr Raveendra Pai, Sr VP, Formulation Development, Glenmark Pharmaceuticals
• Dr Simta Jadhav, VP, Raay Neopharma
• Dr Md Rizwan, DGM, Alkem Laboratories
• Ms Preeti Raut, Technical Consultant, Cipla
• Dr Sunil B Pandey, AVP – R&D (NDDS-Formulation & ADL), Bharat Serums & Vaccines (Subsidiary of Mankind Pharma)
• Dr Premchand Nakhat, Head-Formulation and Technology Transfer, Inventia Healthcare
Key Highlights:
[1] Complex generics are not easy wins. Products like injectables or device combinations take more time, expertise and investment to develop.
[2] AI is slowly entering formulation R&D. Predictive tools can help forecast impurities, compatibility, and product behaviour even before lab work begins.
[3] Speed to market needs strong collaboration. Experienced teams working closely across materials, processes and analytics make complex development faster and smoother
[4] Establishing a strong design space at the lab stage helps avoid unexpected issues during scale-up.
[5] Strong documentation enables smoother scale-up. Clear processes and communication help reduce failures during tech transfer and commercialisation.
[6] Early scientific discussions with agencies like the U.S. Food and Drug Administration can help clarify study requirements and reduce review timelines.
[7] Research work had to be aligned with industry expectation for better industry-academia collaboration.